Paraoxonase 1 (PON1) Polymorphisms, Haplotypes and Activity in Predicting CAD Risk in North-West Indian Punjabis

Background Human serum paraoxonase-1 (PON1) prevents oxidation of low density lipoprotein cholesterol (LDL-C) and hydrolyzes the oxidized form, therefore preventing the development of atherosclerosis. The polymorphisms of PON1 gene are known to affect the PON1 activity and thereby coronary artery disease (CAD) risk. As studies are lacking in North-West Indian Punjabi's, a distinct ethnic group with high incidence of CAD, we determined PON1 activity, genotypes and haplotypes in this population and correlated them with the risk of CAD. Methodology/Principal Findings 350 angiographically proven (≥70% stenosis) CAD patients and 300 healthy controls were investigated. PON1 activity was determined towards paraoxon (Paraoxonase; PONase) and phenylacetate (Arylesterase; AREase) substrates. In addition, genotyping was carried out by using multiplex PCR, allele specific oligonucleotide –PCR and PCR-RFLP methods and haplotyping was determined by PHASE software. The serum PONase and AREase activities were significantly lower in CAD patients as compared to the controls. All studied polymorphisms except L55M had significant effect on PONase activity. However AREase activity was not affected by them. In a logistic regression model, after adjustment for the conventional risk factors for CAD, QR (OR: 2.73 (1.57–4.72)) and RR (OR, 16.24 (6.41–41.14)) genotypes of Q192R polymorphism and GG (OR: 2.07 (1.02–4.21)) genotype of −162A/G polymorphism had significantly higher CAD risk. Haplotypes L-T-G-Q-C (OR: 3.25 (1.72–6.16)) and L-T-G-R-G (OR: 2.82 (1.01–7.80)) were also significantly associated with CAD. Conclusions In conclusion this study shows that CAD patients had lower PONase and AREase activities as compared to the controls. The coding Q192R polymorphism, promoter −162A/G polymorphism and L-T-G-Q-C and L-T-G-R-G haplotypes are all independently associated with CAD.

[1]  Coronary artery disease in South Asians. Second meeting of the International Working Group. 16 March 1997, Anaheim, California. , 1998, Indian heart journal.

[2]  Robert Barouki,et al.  Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. , 2003, Molecular pharmacology.

[3]  G. Jarvik,et al.  Polymorphisms in the human paraoxonase (PON1) promoter. , 2001, Pharmacogenetics.

[4]  K. Bainey,et al.  Coronary Artery Disease in South Asians , 2012, Cardiology in review.

[5]  G. Jarvik,et al.  Determination of Paraoxonase 1 Status Without the Use of Toxic Organophosphate Substrates , 2008, Circulation. Cardiovascular genetics.

[6]  J. Ott,et al.  Power and Sample Size Calculations for Case-Control Genetic Association Tests when Errors Are Present: Application to Single Nucleotide Polymorphisms , 2002, Human Heredity.

[7]  J. Miller,et al.  Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. , 1998, Atherosclerosis.

[8]  P. Durrington,et al.  Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon , 1997, British journal of pharmacology.

[9]  R. Hegele,et al.  A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[10]  M. Meyer,et al.  Multiplex amplification of ancient DNA , 2006, Nature Protocols.

[11]  P. McElduff,et al.  Low Paraoxonase Activity Predicts Coronary Events in the Caerphilly Prospective Study , 2003, Circulation.

[12]  J. Ferrières,et al.  Paraoxonase activity in two healthy populations with differing rates of coronary heart disease , 2000, European journal of clinical investigation.

[13]  V. Steen,et al.  CYP2D6 multiallelism. , 1996, Methods in enzymology.

[14]  C. Furlong,et al.  Purification of rabbit and human serum paraoxonase. , 1991, Biochemistry.

[15]  T. Suehiro,et al.  Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. , 1996, International journal of cardiology.

[16]  M. Najafi,et al.  Paraoxonase 1 gene promoter polymorphisms are associated with the extent of stenosis in coronary arteries. , 2009, Thrombosis research.

[17]  J. Danesh,et al.  Four paraoxonase gene polymorphisms in 11 212 cases of coronary heart disease and 12 786 controls: meta-analysis of 43 studies , 2004, The Lancet.

[18]  R. Singh,et al.  The modernization of Asia. Implications for coronary heart disease. Council on Arteriosclerosis of the International Society and Federation of Cardiology. , 1996, Circulation.

[19]  R. Schmidt,et al.  Paraoxonase PON1 polymorphism leu-Met54 is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study. , 1998, Stroke.

[20]  C. Furlong,et al.  Determination of paraoxonase (PON1) status requires more than genotyping. , 1999, Pharmacogenetics.

[21]  Dan S. Tawfik,et al.  The 'evolvability' of promiscuous protein functions , 2005, Nature Genetics.

[22]  P. Winocour,et al.  Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. , 1991, Atherosclerosis.

[23]  I. Leviev,et al.  Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[24]  P. Malhotra,et al.  Coronary heart disease and its risk factors in first-generation immigrant Asian Indians to the United States of America. , 1996, Indian heart journal.

[25]  E. Birman-Deych,et al.  In utero pesticide exposure, maternal paraoxonase activity, and head circumference. , 2003, Environmental health perspectives.

[26]  C. Walker,et al.  Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. , 1986, Clinical chemistry.

[27]  P. Elwood,et al.  Structural and functional analysis of the human KB cell folate receptor gene P4 promoter: cooperation of three clustered Sp1-binding sites with initiator region for basal promoter activity. , 1995, Biochemistry.

[28]  R. Singh Coronary artery disease in South Asians. , 1997, Indian heart journal.

[29]  A. Montali,et al.  The gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in italian patients. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[30]  S. Deakin,et al.  Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position - 107, implicating the Sp1 transcription factor. , 2003, The Biochemical journal.

[31]  D. Shih,et al.  Combined Serum Paraoxonase Knockout/Apolipoprotein E Knockout Mice Exhibit Increased Lipoprotein Oxidation and Atherosclerosis* , 2000, The Journal of Biological Chemistry.

[32]  M. Keifer,et al.  The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin , 1996, Nature Genetics.

[33]  N. Holland,et al.  PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity , 2006, Pharmacogenetics and genomics.

[34]  O. Lockridge,et al.  Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[35]  B. La Du,et al.  The human serum paraoxonase/arylesterase polymorphism. , 1983, American journal of human genetics.

[36]  D. Sanghera,et al.  Genetic polymorphism of paraoxonase and the risk of coronary heart disease. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[37]  M. Blatter,et al.  Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. , 1993, European journal of biochemistry.

[38]  A. Smolen,et al.  Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[39]  C. Abbott,et al.  Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. , 1994, The Biochemical journal.

[40]  Surjit Singh,et al.  Paraoxonase (PON1) activity in north west Indian Punjabis with coronary artery disease & type 2 diabetes mellitus. , 2007, The Indian journal of medical research.

[41]  M. Jauhiainen,et al.  The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. , 1996, The Journal of clinical investigation.

[42]  A. Todd,et al.  Prospective Study of Blood and Tibia Lead in Women Undergoing Surgical Menopause , 2004, Environmental health perspectives.

[43]  P. Durrington,et al.  Paraoxonase Status in Coronary Heart Disease: Are Activity and Concentration More Important Than Genotype? , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[44]  T. Zama,et al.  A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[45]  P. Froguel,et al.  Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. , 2000, Diabetes.

[46]  P. Moulin,et al.  Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q-->R genetic polymorphism. , 1999, Journal of lipid research.

[47]  Aldons J Lusis,et al.  Thematic review series: The Pathogenesis of Atherosclerosis Published, JLR Papers in Press, April 1, 2004. DOI 10.1194/jlr.R400001-JLR200 The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL , 2004, Journal of Lipid Research.

[48]  A. Smolen,et al.  PURIFICATION OF HUMAN SERUM PARAOXONASE/ARYLESTERASE , 1991 .

[49]  C. Carlson,et al.  Paraoxonase Activity, But Not Haplotype Utilizing the Linkage Disequilibrium Structure, Predicts Vascular Disease , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[50]  L. Hsu,et al.  The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. , 1998, Atherosclerosis.

[51]  P. Durrington,et al.  The paraoxonase gene family and coronary heart disease , 2002, Current opinion in lipidology.

[52]  Y. Ikeda,et al.  A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. , 2000, Atherosclerosis.

[53]  G. Charpentier,et al.  Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes , 1995, The Lancet.

[54]  V. Steen,et al.  [22] CYP2D6 multiallelism , 1996 .

[55]  J. Hokanson,et al.  Paraoxonase genotypes, lipoprotein lipase activity, and HDL. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[56]  P. Durrington,et al.  How high-density lipoprotein protects against the effects of lipid peroxidation , 2000, Current opinion in lipidology.

[57]  T. Parrón,et al.  Paraoxonase activity and genetic polymorphisms in greenhouse workers with long term pesticide exposure , 2003, Human & experimental toxicology.

[58]  M. Marmot,et al.  Association of Early‐Onset Coronary Heart Disease in South Asian Men With Glucose Intolerance and Hyperinsulinemia , 1993, Circulation.

[59]  S. Malcolm,et al.  Genotype to phenotype , 2001 .

[60]  A. Montali,et al.  PON1 L55M polymorphism is not a predictor of coronary atherosclerosis either alone or in combination with Q192R polymorphism in an Italian population , 2002, European journal of clinical investigation.

[61]  G. Jarvik,et al.  Paraoxonase 1 status as a risk factor for disease or exposure. , 2010, Advances in experimental medicine and biology.

[62]  D. Shih,et al.  Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis , 1998, Nature.

[63]  G. Schellenberg,et al.  Paraoxonase (PON1) Phenotype Is a Better Predictor of Vascular Disease Than Is PON1192 or PON155 Genotype , 2000, Arteriosclerosis, thrombosis, and vascular biology.